Management of chronic myeloid leukemia in 2023 – common ground and common sense

With the improving knowledge of CML and its management, the goals of therapy need to be revisited to ensure an optimal use of the BCR::ABL1 TKIs in the frontline and later-line therapy of CML. In the frontline therapy of CML in the chronic phase (CML-CP), imatinib and the three second-generation TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Senapati, Jayastu, Sasaki, Koji, Issa, Ghayas C., Lipton, Jeffrey H., Radich, Jerald P., Jabbour, Elias, Kantarjian, Hagop M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123066/
https://www.ncbi.nlm.nih.gov/pubmed/37088793
http://dx.doi.org/10.1038/s41408-023-00823-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123066/
https://www.ncbi.nlm.nih.gov/pubmed/37088793
http://dx.doi.org/10.1038/s41408-023-00823-9

Ejemplares similares